NEW YORK (GenomeWeb) – Swedish diagnostic developer Immunovia said today that it has established a US subsidiary in Boston. The facility will house a CLIA reference lab and commercialization operations for the firm, which is preparing to launch its first test — a liquid biopsy assay for pancreatic cancer called Immray PanCan-d — in the first half of 2018.
"This East coast laboratory complements the existing collaboration we have with Knight Diagnostic Laboratories in Portland, serving Western USA," Immunovia CEO Mats Grahn said in a statement.
Immunovia's core Immray technology platform is based on antibody biomarker microarray analysis.
Separately today, Qlucore announced that its Omics Explorer data-analysis software will be used by Immunovia.
Qlucore's software provides workflows and tools for analyzing and exploring genomics data. The company recently introduced a next-generation sequencing module that features an interactive genome browser and filter options.
"At Immunovia we routinely explore and analyze large data sets within our research and development," Grahn said. "Qlucore Omics Explorer is helping us to perform complex analysis smoothly and correctly … [and] forms an integral part of our research work."